Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Quantum Base wins £0.25m contract extension

(Sharecast News) - Quantum Base announced a £0.25m expansion of its contract with its largest customer, a major international security printer, on Tuesday, adding to a previous £0.1m extension agreed earlier in the year. The AIM-traded firm said the additional revenue would be recognised in the current financial year ending 30 April.

It said the agreement, which allowed the customer to market and sell Quantum Base's Q-ID technology, was initially deployed on government tax stamps.

The expanded contract would broaden support to 170 smartphone models, covering more than 99% of usage in the company's target markets.

"I am delighted to announce the expansion of our contract with our largest customer - a significant commercial partnership for Quantum Base," said chief executive Tom Taylor.

"When we initially signed the agreement, it represented the first large-scale commercialisation of Q-ID technology.

"The decision to broaden the programme scope and advance our relationship at this relatively early stage serves as a strong indication of the real-world value that our product is delivering."

He added that trading remained in line with expectations, and that the company still anticipated signing four more commercial contracts by April 2026.

"Counterfeiting is on the rise globally, and we're experiencing high demand for our world leading innovation," Taylor said.

At 1419 BST, shares in Quantum Base Holdings were up 9.93% at 18.14p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.